Dear Colleagues,

The emergence and re-emergence of viruses represent a major concern for the human population, as illustrated by frequent outbreaks since the beginning of the century. Climate change, lifestyle, population density, and the vicinity to wild animals and livestock contribute to the increasing number of viral emergences. Unfortunately, the recent SARS-CoV-2 outbreak has highlighted that there is still a major gap to fill to be better prepared for and respond to such events. Regarding antivirals, it implies the development of broad-spectrum antiviral drugs for unexpected emerging agents as well as optimized therapeutics to cure targeted agents with a high probability of (re)emergence. In this Special Issue, we would like to promote the development and characterization of antivirals against emerging viruses or viruses with the potential for emergence. The Special Issue will focus on the early stages of drug development to preclinical studies, including target discovery, antiviral screening and optimization, and the mode of action. Contributions exploring the development of innovative technologies related to the antiviral field such as screening assays, animal models, and reverse genetics systems are also welcome. As the scope of this Special Issue, “Antiviral Therapeutics against Emerging Viruses”, is quite vast, we are restricting it to zoonotic and human diseases.

Prof. Dr. Bruno Coutard
Dr. Franck Touret
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• emerging viruses
• antiviral screening
• drug design
• animal model
• mode of action

• Antiviral Therapeutics for Emerging Viruses in Viruses (9 articles)